EU Moves Toward First Gene Therapy for Wiskott-Aldrich Syndrome The European Medicines Agency (EMA) has recommended granting marketing authorization in the European Union for Waskyra (etuvetidigene autotemcel), a gene therapy designed to treat people aged 6 months and older with Wiskott-Aldrich syndrome (WAS) who carry mutations in the WAS gene. If approved, Waskyra would become…